DexCom, Inc. $DXCM Shares Acquired by WINTON GROUP Ltd

WINTON GROUP Ltd lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 226.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 136,493 shares of the medical device company’s stock after acquiring an additional 94,631 shares during the quarter. WINTON GROUP Ltd’s holdings in DexCom were worth $9,193,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Reflection Asset Management purchased a new stake in DexCom during the 4th quarter worth about $25,000. Ascentis Independent Advisors acquired a new position in shares of DexCom during the first quarter worth about $25,000. MCF Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth approximately $32,000. Wellington Grp LLC raised its holdings in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 475 shares in the last quarter. Finally, DV Equities LLC acquired a new stake in DexCom in the fourth quarter valued at approximately $36,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Kevin Sayer sold 26,756 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares in the company, valued at $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the transaction, the executive vice president directly owned 126,043 shares of the company’s stock, valued at approximately $11,138,419.91. This trade represents a 1.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,777 shares of company stock valued at $4,950,714 over the last 90 days. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $83.88 on Thursday. The company has a market capitalization of $31.65 billion, a P/E ratio of 33.15, a PEG ratio of 1.42 and a beta of 1.42. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The business has a 50 day simple moving average of $82.25 and a 200-day simple moving average of $72.65. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the previous year, the company posted $0.48 EPS. The company’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DXCM. Robert W. Baird set a $105.00 price target on shares of DexCom in a research note on Friday, July 31st. Mizuho raised their price objective on shares of DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft initiated coverage on shares of DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price for the company. BTIG Research restated a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Finally, Citigroup reaffirmed a “buy” rating and set a $88.00 price target (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.